Introduction and Objectives
===========================

During the last two decades, the molecular events that lead to the formation of renal cell carcinoma have been elucidated, particularly for the clear cell type (ccRCC). Most clear cell renal tumors form as the result of dysregulation of the von Hippel-Lindau tumor (*VHL*) suppressor gene with loss-of-function somatic mutations and epigenetic silencing that may be found in up to 90% of sporadic ccRCC [@B1]. While the inciting genetic events that lead to the formation of ccRCC have been worked out in great detail, the events that give primary tumors the ability to grow and potentially gain aggressiveness remain poorly understood.

There is a strong relationship between the size of the primary tumor and likelyhood of metastasis. Frank et al demonstrated that estimated cancer specific survival rates for tumors \>7cm were 15-25% higher than for tumors that were less than \<7cm following nephrectomy [@B2]. In a separate study from the NCI of a cohort of patients with inherited germline mutations of the *VHL* gene, there have been no cases of metastasis of tumors less than 3 cm [@B3]. To explore the genetic events involved in the development and progression of ccRCC as tumors grow larger, we surveyed the global gene expression profiles of tumors of different sizes in patients with confirmed germline *VHL* gene mutations. By using tumors of different sizes removed from the same patient, we aimed to study the differences in genetic profiles associated with increase in tumor size.

Materials/Methods
=================

Patient selection
-----------------

Pathology reports from patients who underwent partial nephrectomies for multiple renal tumors at the National Cancer Institute were reviewed. Eleven patients fulfilled the following inclusion criteria: 1) The patient must have had a surgical resection of more than one solid tumor from the same kidney during the same operation; 2) Among the solid tumors at least one must have been greater than 3 cm in the largest dimension while the other removed solid tumor was less than 2 cm; 3) the nuclear Furhman grade for both larger and smaller solid tumors was identical; 4) a portion of each tumor was procured and snap frozen after surgical removal; 5) Hematoxylin and eosin staining of the frozen sample confirmed clear cell carcinoma to be present in at least 80% of the section. Original tumor volumes were calculated using the formula for an ellipsoid (4/3πr^3^). All patients had confirmed mutations in the VHL tumor suppressor gene. All patients were enrolled in an IRB approved NIH intramural research protocol.

A summary of the tumor sizes for the eleven patients included in this study can be seen in Table [1](#T1){ref-type="table"}. Four pairs have at least 1 tumor \>4cm (used to compare T1a vs T1b), and seven pairs have two tumors \<4cm (used to compare T1a vs T1a).

An example of the multifocal renal tumors in a patient with VHL disease can be seen in the bivalved nephrectomy specimen in Figure [1](#F1){ref-type="fig"} demonstrating multiple tumors of different sizes throughout the kidney.

RNA Isolation
-------------

Fifteen 20μm thick frozen sections from each tissue sample were homogenized in TRIZOL reagent (Invitrogen Life Techonolgies, Carlsbad, CA USA). Total RNA was extracted using a standard chloroform protocol followed by purification with the Qiagen RNeasy Mini Kit (QIAGEN Inc, Valencia, CA USA). RNA integrity was evaluated by using RNA 6000 Nano LabChips on an Agilent 2100 Bioanalyzer (Agilent Technologies, Foster City, CA USA). RNA purity was assessed by the ratio of spectrophotometric absorbance at 260 and 280 nm (A260/280nm) using NanoDrop ND-1000 (NanoDrop Inc, Wilmington, DE USA). All chips were prepared according to the manufacturer\'s instructions. Total RNA degradation was evaluated by reviewing the electropherograms and the RNA integrity number (RIN): only samples with preserved 18S and 28S peaks and RIN values greater than 7 were selected for gene expression analysis.

Microarray hybridization and Image Acquisition
----------------------------------------------

Messenger RNA expression levels were measured using the GeneChip® HG-U133 plus 2.0 platform following the manufacturer\'s protocol (Affymetrix Inc, Santa Clara, CA USA). Briefly, double-stranded cDNA was synthesized from 11µg of total RNA from each tumor sample using GeneChip Two-Cycle cDNA Target Synthesis Kit (Affymetrix Inc, Santa Clara, CA USA). After one round of amplifications, in vitro transcription was performed using IVT Labeling Kit (Affymetrix Inc, Santa Clara, CA USA) to synthesize biotin-labeled cRNA. An aliquot of 15ug labeled cRNA was fragmented and subsequently hybridized for 16 hours at 45C in a hybridization oven to a HG-U133 plus 2.0 olgionucleotide array. Arrays were washed and scanned with an Affymetrix GeneChip 3000 Scanner.

Statistical Analysis
--------------------

Raw data (.CEL) files were imported into BRB array tools [@B4]. The data were normalized using the RMA algorithm [@B5]. Unsupervised clustering was performed using hierarchical clustering (1-correlation) based on the differences in size between large and small tumors. The data were then separated into two groups for supervised analysis: the first consisted of pairs of tumors that were both T1a (\<4cm), and the second group had one T1a tumor and one T1b (between 4 and 7 cm) to evaluate the accepted size cut offs of AJCC staging. Differences in gene expression were analyzed using a paired t-test with random variance model set at 1000 permutations. Significant P-value was set at 0.01. BRB array tools was used to analyze which categories are over-represented relative to the prevalence of Gene Ontology categories on the array [@B4].

Data were then imported into the R environment for further analysis ([www.r-project.org](http://www.r-project.org)). Chromosomal abnormalities were assessed with a technique known as comparative genomic microarray analysis. This method has been shown to have good correlation with more traditional CGH techniques [@B6]. For a common reference pool, a pool of normal renal parenchyma from the gene expression omnibus database (<http://www.ncbi.nlm.nih.gov/geo/>) was used (GSE7392).

Results
=======

The results of unsupervised clustering based on the volume difference of the pairs can be seen in Figure [2](#F2){ref-type="fig"}. With one exception, the pairs with larger differences in volume clustered separately from pairs with smaller differences.

A schematic of the results of the paired t-test are observed in figure [3](#F3){ref-type="fig"}. The Affymetrix HGU133 plus 2.0 has 54,675 probe sets. The threshold for significance was set at 0.01. Thus, we would expect approximately 550 false positives. In the paired analysis where both tumors were less than 4cm, there were 458 genes were differentially expressed, less than would be expected by chance. When tumors greater than 4cm were compared to tumors less than 4cm in the same patient, there were 890 differentially expressed genes identified, which is greater than the expected false positives. When we examined the gene ontology of the significant gene changes, we found that transcripts involved in cytokine production and DNA synthesis to be over-represented (Table [2](#T2){ref-type="table"}).

The first part of the cGMA chromosomal analysis was an examination of the expression pattern for chromosome 3. Since all the patients had a confirmed VHL mutation, as expected the level of expression was decreased in chromosome 3p25 in all samples when compared to normal renal parenchyma (Figure [4](#F4){ref-type="fig"}). Interestingly, there is was also a decrease in gene expression near chromosome 3p21. Full chromosomal analysis revealed that the expression profiles within each pair appeared similar. No consistent differences in expression on chromosomal level between large and small tumors were observed. (Figure [5](#F5){ref-type="fig"}).

Discussion
==========

Renal tumors in patients with von Hippel Lindau syndrome result from biallelic inactivation of the *VHL* gene located on chromosome 3p25 with one allele inactivated via a germline mutation and the second due to a random somatic event [@B7]. The protein product of the *VHL* gene (pVHL) is a key component of an ubiquitin ligase complex that marks the alpha subunit of hypoxia inducible factor (HIF) for degradation [@B8]. The VHL protein serves a critical role in prevention of dysregulated HIF-alpha levels [@B9]. Downregulation of HIF-a by pVHL has been shown to be both necessary and sufficient for renal tumor suppression. In the absence of pVHL patients are prone to form tumors of the retina, CNS, kidneys, pancreas, and epididymis [@B10].

Among the most severe manifestations of the VHL syndrome are the renal manifestations. These patients are at risk for forming multiple bilateral clear cell renal cell carcinomas - as many as 70 clinically lesions in one kidney have been documented to be removed [@B11]. Despite multiple foci of disease that cumulatively represent substantial tumor burden, the renal tumors in patients with VHL do not attain the ability to metastasize until the largest tumor reaches 3cm [@B3]. Similar to VHL tumors, size of sporadic renal masses is also one of the most important prognostic indicators in sporadic RCC. Frank et al estimated 5 year survival rates to be 97% for patients with T1a (\<4cm) tumors, 87% for patients with T1b tumors (4-7 cm), and 71 % for patients with T2 disease (\>7cm) [@B2]. While the relationship between size and metastatic potential is well-established, molecular changes that are associated with tumor growth are poorly characterized.

In the present study we investigated the changes in gene expression profiles that occur with tumor growth by performing microarray analysis on small and large tumors from the same patient. Interestingly, unsupervised clustering revealed that the tumor pairs with larger volume differences clustered separately from tumor pairs with smaller volume differences. This suggests that the global transcriptome of larger tumors are more biologically dissimilar from smaller tumors within the same patient. Such observation is of potential clinical relevance as these tumors were not only resected from the same patient and the same kidney, they had the same germline mutation, and were exposed to the same environmental and host factors throughout their development. Therefore, the differences observed may be representative of biologically significant processes because the only difference between the tumors was their size.

We were also able to investigate the nature of the genetic changes on a chromosomal level between large and small tumors. CGMA was used to examine gene expression changes between tumor samples and a pool of normal renal parenchyma samples. Analysis of the gene expression from each chromosome revealed only one area that had decreased expression across all samples: 3p - the location of the VHL gene. These findings are also useful as confirmatory results of our analysis, demonstrating global loss of gene expression on the 3p, consistent with the VHL samples studied.

In addition to demonstration of 3p loss as a confirmation of our analyses, the study of cytogenetics may be particularly relevant in patients with VHL. Indeed, inactivation of pVHL was found to lead to defects in spindle orientation thus provoking chromosomal instability [@B12]. Consistent with this theory, multiple chromosomal abnormalities have been reported in the literature for patients with both hereditary and sporadic ccRCC [@B13], [@B14]. For example, Phillips et al performed cytogenetic studies on cell lines derived from vHL patients with multifocal RCC and found that higher stage tumors were associated with a greater degree of aneupolidy [@B14].

Notably, not all studies demonstrated genomic instability in RCC. A study of the sporadic ccRCC population failed to show an association between the degree of genomic instability and the clinical stage of renal tumors [@B13]. Interestingly, another large scale study of 432 clear cell renal tumors supported the loss of chromosome 3p as a common event in the development of ccrCC (60%), but the prevalence of other chromosomal aberrations were much lower (14% for loss of chromosome 4p to 33% for gain of chromosome 5q). In that study, loss of chromosome 9 was the only independent predictor associated with survival [@B15]. The lack of chromosomal changes between larger and smaller tumors in our study is inconsistent with the concept that chromosomal instability occurs in larger tumors. However, it should be noted that all our samples are derived from T1 tumors, which are associated with a very good prognosis. In contrast, the tumors studied by Phillips et al included a wider spectrum of disease, including tumors that had achieved the ability to metastasize [@B14]. Therefore, chromosomal instability may be a late, rather than an early event, in tumor progression.

While consistent cytogenetic changes between large and small tumors were not observed, we did note significant changes in the expression of individual genes. For this analysis, our sample was split into two groups: groups where the larger tumor was less than 4 cm (T1a) and groups where the larger tumor was greater than 4cm (T1b). As Figure [3](#F3){ref-type="fig"} demonstrates, the number of statistically significant genetic changes between large and small tumors was no greater than would be expected by random chance when both tumors were T1a. This finding further supports the strategy used at the urologic oncology branch at the NCI, when small tumors are surveilled until the largest tumor reaches 3 cm (Duffey at al). However, once the largest tumor reached T1b size (greater than 4cm), the number of statistically significant genetic changes between larger and smaller tumors becomes much greater than would be expected by random chance. This suggests that even in the absence of large cytogenetic changes, there are significant changes in gene expression as tumors grow larger. When Gene Ontology analysis was performed, it demonstrated that there was an over-representation of transcripts involved in DNA replication and in cytokine signaling, particularly IL-6. This may be clinically elevant, especially since cytokine therapy is one of the durable treatments used for advanced ccRCC.

This study represents one of the first attempts to perform microarrays on tumors derived from the same patient. Gieseg studied the gene expression profiles of smaller (200mg) and larger tumors (1000 mm) in subcutaneously grown tumors from cell lines, and found no difference in gene expression between large and small tumors [@B16]. This is not unexpected as a cell line represents a clonal population of cells that has been selected for high proliferative ability. Perou et al examined breast cancer samples derived from primary tumor and lymph nodes in the same patient, and found that gene expression patterns in two tumor samples from the same individual were almost always more similar to each other than either was to any other sample [@B17]. Similarly, Chen et al examined multiple tumors from patients with HCC [@B18]. The investigators noted that the most important factor in clustering was the individual of origin, not the size of the tumor. They found genetic differences between clonally related tumors. Consistent with our findings, the differences were particularly evident in one patient with a large tumor (8cm), who had different chromosomal abnormalities than smaller tumors in the same patient (1cm and 2cm) [@B18].

The results of prior studies on tumors from the same patient corroborate our data. It appears that each individual has a very distinct pattern of transcribed genes when surveyed by gene expression microarray. Tumors have genetic aberrations, but continue to have a transcriptome that is more similar to its parental pattern than to another individual\'s transcriptome. Our data provide evidence of differences in gene expression between larger and small renal cell carcinoma tumors, although the number of differences may small in number in T1 renal tumors. It may not be until renal tumors are even larger that chromosome instability would be detectable.

Of note, our size criteria were chosen to reflect a clinically useful landmark. Tumors less than 4cm are also known as small renal masses. As the use of CT scans increases, the incidence of these small renal masses is rising, creating a new debate about the utilization of active surveillance in select patients [@B19]. We found that there may be a biologic basis for this practice by demonstrating few genetic differences in T1a tumors. Consistent with our findings, recent work from MSKCC studying metastatic events of sporadic RCC, found the metastatic rate negligible in patients with renal masses less than 3cm [@B20]. However, as the size of the tumors increases beyond 4 cm, there are ongoing changes in the transcriptome, possibly reflecting the potential change in biologic aggressiveness.

The present study has a few limitations. First, the samples analyzed were archived, and there is a possibility that some of the observed changes may be due to a length of storage and procurement conditions. Second, although all patients had VHL, the different germline mutations or the second hits of the normal allele may have also be a variable, determining the expression profile of the tumors studied. Third, the sample size is small (although it includes patients treated during a period of 5 years at the NCI). Finally, we recognize that the transcriptome analysis do not always translate into proteome and biologic significance. Despite these limitations, this is the first study in RCC that compares the expression levels of large and small tumors obtained from the same individual in the same setting. Additionally, his study may provide new biologic rationale for active surveillance of small renal masses, practiced for years at the National Cancer Institute.

Conclusion
==========

Through analysis of genetic expression profiles between larger and smaller tumors in the same patient, we found that larger tumor volume differences progressively increased global transcriptome changes. Although few changes in gene expression were appreciated on a chromosomal level, on the level on the individual transcripts, there were an increasing number of changes between large and small tumors, especially when the larger tumor was greater than 4cm (T1b). This may provide a genetic rational behind active surveillance of small renal masses in select patients and further support practice of active surveillance at the Urologic Oncology Branch at the NCI.
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![Comparative genomic microarray analysis - global chromosomal heat map. No consistent differences in expression on chromosomal level between large and small tumors were observed. Note that the changes between individuals are greater than changes between tumors of different size in a given individual.](jcav02p0271g05){#F5}

###### 

Tumor sizes for the patients

               Size    Tumor size (cm)   Size Difference (cm)   Tumor volume (cc^3^)   Volume Difference (cc^3^)
  ------------ ------- ----------------- ---------------------- ---------------------- ---------------------------
  Patient 1    large   6                 4.7                    84.8                   84.0
               small   1.3                                      0.8                    
  Patient 2    large   5.5               3.7                    25.9                   24.5
               small   1.8                                      1.4                    
  Patient 3    large   5.2               4                      34.3                   31.9
               small   1.2                                      2.4                    
  Patient 4    large   4.5               2.5                    24.7                   22.0
               small   2                                        2.7                    
  Patient 5    large   3.5               1.7                    11.9                   11.4
               small   1.8                                      0.5                    
  Patient 6    large   3.5               2                      9.2                    8.9
               small   1.5                                      0.3                    
  Patient 7    large   3.4               2.1                    15.9                   15.3
               small   1.3                                      0.6                    
  Patient 8    large   3.1               1.1                    11.8                   10.3
               small   2                                        1.5                    
  Patient 9    large   3                 1                      4.7                    2.3
               small   2                                        2.4                    
  Patient 10   large   3                 1.6                    7.9                    6.8
               small   1.4                                      1.1                    
  Patient 11   large   3                 1.8                    14.1                   13.8
               small   1.2                                      0.3                    

###### 

Gene ontology

  GO ID        GO Term                                             Observed/Expected
  ------------ --------------------------------------------------- -------------------
  GO:0032602   chemokine production                                8.08
  GO:0042364   water-soluble vitamin biosynthetic process          6.79
  GO:0051187   cofactor catabolic process                          6.57
  GO:0034381   lipoprotein particle clearance                      6.47
  GO:0009110   vitamin biosynthetic process                        5.5
  GO:0006306   DNA methylation                                     5.39
  GO:0006305   DNA alkylation                                      5.39
  GO:0007031   peroxisome organization                             4.85
  GO:0031047   gene silencing by RNA                               4.53
  GO:0006304   DNA modification                                    4.04
  GO:0030336   negative regulation of cell migration               3.99
  GO:0001935   endothelial cell proliferation                      3.93
  GO:0016458   gene silencing                                      3.85
  GO:0043542   endothelial cell migration                          3.83
  GO:0009062   fatty acid catabolic process                        3.83
  GO:0045765   regulation of angiogenesis                          3.7
  GO:0051271   negative regulation of cell motion                  3.64
  GO:0043414   biopolymer methylation                              3.45
  GO:0045762   positive regulation of adenylate cyclase activity   3.38
  GO:0019362   pyridine nucleotide metabolic process               3.31
  GO:0022618   ribonucleoprotein complex assembly                  3.17
  GO:0006733   oxidoreduction coenzyme metabolic process           3.17
  GO:0031281   positive regulation of cyclase activity             3.16
  GO:0051349   positive regulation of lyase activity               3.1

[^1]: ^\#^ Equal contribution

[^2]: Conflicts of Interest: The authors have no conflicts of interest to report
